WO2009092134A1 - Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season - Google Patents

Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season Download PDF

Info

Publication number
WO2009092134A1
WO2009092134A1 PCT/AU2009/000065 AU2009000065W WO2009092134A1 WO 2009092134 A1 WO2009092134 A1 WO 2009092134A1 AU 2009000065 W AU2009000065 W AU 2009000065W WO 2009092134 A1 WO2009092134 A1 WO 2009092134A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
thebaine
poppy
seed
germination
Prior art date
Application number
PCT/AU2009/000065
Other languages
French (fr)
Inventor
Jarrod David Ritchie
Original Assignee
Tpi Enterprises Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008900325A external-priority patent/AU2008900325A0/en
Application filed by Tpi Enterprises Pty Ltd filed Critical Tpi Enterprises Pty Ltd
Priority to CN2009801090411A priority Critical patent/CN101969760A/en
Priority to US12/735,548 priority patent/US20110047653A1/en
Priority to AU2009208009A priority patent/AU2009208009B2/en
Priority to EP20090703922 priority patent/EP2234473A4/en
Priority to NZ586953A priority patent/NZ586953A/en
Publication of WO2009092134A1 publication Critical patent/WO2009092134A1/en
Priority to ZA2010/05619A priority patent/ZA201005619B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H5/00Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
    • A01H5/02Flowers
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/64Papaveraceae, e.g. poppy

Definitions

  • the present invention relates to poppy cultivars and their use to produce thebaine.
  • the present invention relates to cultivars of Papaver bracteatum that produce thebaine in the first growing season after germination.
  • Opium poppy is commercially cultivated in a number of countries under regulatory control.
  • the latex obtained by the incision of unripe capsules is known as opium and is the source of several pharmacologically important alkaloids.
  • Morphine, codeine, thebaine, narcotine and papaverine are the most important alkaloids produced by the plant, and are exploited by the pharmaceutical industry as analgesics, antitussives and antispasmodics.
  • poppy straw and straw concentrate are the most commonly used raw materials for the production of morphine and other poppy-derived alkaloids.
  • poppy straw and straw concentrate are the most commonly used raw materials for the production of morphine and other poppy-derived alkaloids.
  • more than 50% of the world's morphine is now manufactured from poppy straw or poppy straw concentrate.
  • Thebaine is one of the phenanthrene alkaloids contained in opium poppies.
  • Thebaine is dehydromorphine 3,6-dimethyl ether, which has the structure set out below:
  • the chemical structure of thebaine is superficially similar to both morphine and codeine, but produces stimulatory effects rather than depressant effects. Due to the pharmacological properties of thebaine, it is not generally used therapeutically. However, thebaine may be converted into a variety of pharmaceutical agents including oxycodone, oxymorphone, nalbuphine, naloxone, naltrexone, buprenorphine and etorphine.
  • Australia produces a significant portion (approximately 30% in 2006) of the world's poppy straw concentrates for morphine production.
  • the Australian State of Kenya is the world's largest producer of opium alkaloids for the pharmaceutical market. The area sown to poppies in Kenya was close to 8,000 ha in 2006.
  • the present invention is predicated, in part, on the breeding of poppy cultivars that produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • the poppy plants of the present invention which produce seed capsules and an extractable quantity of thebaine in the first growing season after germination are of the species Pa ⁇ aver bracteatum.
  • the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region. In yet another embodiment, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region in the Southern hemisphere.
  • the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in Georgia, Australia.
  • the present invention also provides reproductive material derived from the plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
  • the present invention also provides straw produced from a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
  • the present invention also provides a straw concentrate produced from a plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
  • the present invention also provides latex derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
  • the present invention also provides a stand of stably reproducing poppy plants from which an extractable quantity of thebaine may be produced in the first growing season after germination of the poppy plants, the stand comprising one or more plants according to the first aspect of the invention, or a progeny, mutant or derivative thereof.
  • the present invention also extends to a method of producing thebaine, the method comprising growing a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof, such that the plant produces seed capsules and thebaine in the first growing season after germination; and harvesting thebaine from the poppy plant or a part thereof.
  • the present invention provides an isolated cell derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
  • the present invention also extends to an in-vitro culture including one or more of the cells described above.
  • Exemplary "in-vitro cultures” contemplated herein include, for example, callus cultures and suspension cultures which include one or more of the cells of the invention.
  • the in-vitro cultures of the present invention may be used to produce thebaine.
  • the present invention provides a poppy plant which produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • a "poppy plant” should be understood to refer to any thebaine- producing member of the genus Papaver.
  • Exemplary species within the genus Papaver include the Papaver species described in Table 1.
  • the term "poppy” should also be understood to refer to thebaine-producing hybrid plants wherein at least one of the parents is a plant of the genus Pa ⁇ aver.
  • the term "poppy plant” refers to a perennial poppy plant.
  • a “perennial" poppy plant encompasses poppy plants that produce seed capsules and an extractable quantity of an alkaloid such as thebaine for more than one growing season without the need to replant.
  • the term "poppy plant” refers to a poppy plant of the species Pa ⁇ aver bracteatum or a hybrid poppy plant wherein at least one of the parents of the hybrid plant is a poppy plant of the species Pa ⁇ aver bracteatum.
  • poppy plant may also include derivatives and mutants of poppy plants.
  • poppy plant may refer to a whole poppy plant, but may also refer to a part of a poppy plant, including, for example, reproductive material (such as seeds) derived from a poppy plant; a cell, tissue or organ derived from a poppy plant; and the like.
  • reproductive material such as seeds
  • the poppy plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • the term "thebaine” should be understood as dehydromorphine 3,6-dimethyl ether, which has the structure set out below:
  • An extractable quantity of thebaine should be understood to be any amount of thebaine that may be extracted from the plant, or any part thereof (such as straw or latex).
  • thebaine and related alkaloids may be extracted from dried poppy heads and poppy straw using the methods described in French patent 748308, and various modifications thereof.
  • thebaine is extracted from poppy seed capsules using either aqueous acidic extraction conditions or aqueous alkaline extraction conditions to which various water miscible organic solvents have been added.
  • the extractable quantity of thebaine is a relatively high concentration of thebaine within the plant or a part thereof.
  • the extractable quantity of thebaine may comprise, for example, anhydrous thebaine comprising at least 1.0% by weight of the seed capsules by weight of a seed capsule of the plant when dried to a moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
  • LOD Loss On Drying
  • the extractable quantity of anhydrous thebaine may comprise, for example, at least 1.5%, at least 2.0%, at least 2.5%, at least 3.0%, at least 3.5%, at least 3.6%, at least 3.7% or at least 3.8% by weight of the seed capsules by weight of a seed capsule of the plant when dried to a moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
  • LOD Loss On Drying
  • the concentration of thebaine in P. bracteatum seed capsules may by assessed using any suitable method.
  • any suitable method for example, reference is made to the methods disclosed by Wu and Dobberstein (Journal of Chromatography A 140(1): 65-70, 1977) and Shou et al. (Rapid Communications in Mass Spectrometry 16: 1613-1621, 2002).
  • Production of seed capsules and an extractable quantity of thebaine "in the first growing season after germination” should be understood as the plants producing seed capsules and an extractable quantity of thebaine within one year of seed germination.
  • the plants produce flowers within about 160 days after sowing, and/or are suitable for harvesting and thebaine extraction at about 330 days after sowing.
  • the plants of the present invention which produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at a least temperate poppy growing region.
  • a temperate poppy growing region should be understood as a region in which poppies may be cultivated which is located at a latitude that lies between the tropics and the polar circles.
  • the north temperate zone extends from the Tropic of Cancer at about 23.5 degrees north latitude to the Arctic Circle at about 66.5 degrees north latitude.
  • the south temperate zone extends from the Tropic of Capricorn at about 23.5 degrees south latitude to the Antarctic Circle at about 66.5 degrees south Latitude.
  • the temperate poppy growing region may include a region where the poppies of the present invention will grow which is at one or more latitudes of about 34°, about 35°, about 36°, about 37°, about 38°, about 39°, about 40°, about 41°, about 42°, about 43°, about 44°, about 45°, about 46°, about 47°, about 48°, about 49°, and/or about 50°.
  • the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region in the Southern hemisphere.
  • the plants of the present invention may produce seed capsules and an extractable quantity of thebaine in the first growing season after germination at one or more latitudes of about 34° S, about 35° S, about 36° S, about 37° S, about 38° S, about 39° S, about 40° S, about 41° S, about 42° S, about 43° S, about 44° S, about 45° S, about 46° S, about 47° S, about 48° S, about 49° S, and/or about 50° S.
  • latitude a latitude “about” a particular latitude should be understood to encompass latitudes ⁇ 0.5° of the defined latitude.
  • reference to "one or more latitudes” should be understood to encompass discreet ranges of latitudes bounded by any pairs of the specific latitudes mentioned above.
  • the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination at a latitude of between about 40° S and about 44° S.
  • the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in Georgia, Australia or a region having substantially equivalent climate.
  • the average rainfall and temperatures in Kenya vary considerably across the state. However, in the main poppy growing regions in the north-west and midlands of the state, the typical rainfall is in the range of 600 to 800 mm, and the minimum / maximum temperatures are 2°C and 12°C respectively for July and 12°C and 24°C for January and February. Typically, in Kenyan poppy growing regions, poppies are planted in March and the dried poppy heads are harvested in the following February.
  • Reference herein to a "region having substantially equivalent climate” refers to a region having equivalent day length, rainfall and/or seasonal temperature minima and maxima such that conditions under which poppies may be grown are equivalent to those in Georgia, Australia.
  • the poppy plants of the present invention may have either a dehiscent (open) seed capsule or an indehiscent (closed) seed capsule at seed maturity.
  • Wild type P. bracteatum, and most other Papaver species form pores of dehiscence in the seed capsule at seed maturity, which allows the mature seed in the seed capsule to be released from the seed capsule.
  • the poppy cultivar may have seed capsules that have reduced or no pores of dehiscence at the time the seed in the seed capsule has matured.
  • the trait of an indehiscent or closed seed capsule at maturity leads to the retention of mature seed in the seed capsule in cultivars having the trait.
  • PB-I Seed from the first exemplary cultivar, referred to herein as PB-I, having an indehiscent or closed seed capsule at maturity, has been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41534.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • the plant of the first aspect of the invention is produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41534; or a progeny, mutant or derivative of said plant that retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • PB-2 Seed from the second exemplary cultivar, referred to herein as PB-2, having a dehiscent or open seed capsule at maturity, has been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41535.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • the plant of the first aspect of the invention is produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB; or a progeny, mutant or derivative of said plant that retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • the present invention also provides a progeny plant, wherein the progeny plant has a plant of the first aspect of the invention as a parent, and wherein said progeny plant produces an extractable quantity of thebaine in the first growing season after germination.
  • a progeny plant may be any plant for which a plant of the first aspect of the invention is at least one of the parents.
  • the progeny plant may be a plant resulting from self-fertilisation of a plant of the first aspect of the invention; a plant resulting from a non-self fertilisation wherein a plant of the first aspect of the invention is the male or female parent; an intrageneric hybrid plant wherein one of the parents is a plant of the first aspect of the invention and the other parent is a plant within the genus Papaver; an intergeneric hybrid plant wherein one of the parents is a plant of the first aspect of the invention and the other parent is a plant of a genus other than Papaver, an asexually produced progeny of a plant of the first aspect of the invention, such as vegetatively reproduced progeny or progeny produced by apomixis.
  • the present invention also provides a mutant or derivative of the poppy plant of the first aspect of the invention wherein the mutant or derivative produces seed capsules an extractable quantity of thebaine in the first growing season after germination.
  • a "mutant or derivative" of the subject poppy plants should be understood to encompass, for example, any spontaneous or induced mutant, breeding progeny or genetically modified form of the deposited strains which retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • Mutagenisation techniques that may be used to generate derivatives or mutants of the deposited poppy cultivars include, for example, chemical mutagenesis (eg. EMS mutagenesis), ionising radiation-induced mutagenesis (eg. X-ray mutagenesis, ⁇ -ray mutagenesis and UV mutagenesis), genetic insertion mutagenesis methods (eg. transposon mutagenesis or T-DNA mutagenesis) and the like.
  • Techniques for the production of mutagenized seed are well known in the art. For example, methods of seed mutagenesis as well as chemical mutagens suitable for use in these methods are described in, for example, The Manual on Mutation Breeding, 2nd ed.
  • Example mutagens include ethyl methanesulfonate (EMS), diepoxybutane (DEB) ethyl- 2-chloroethyl sulphide, 2-chloroethyl-dimethylamine, ethylene oxide, ethyleneimine, dimethyl sulphonate, diethyl sulphonate, propane sulphone, beta-propiolactone, diazomethane, N-methyl-N-nitrosourethane, acridine orange and sodium azide.
  • EMS ethyl methanesulfonate
  • DEB diepoxybutane
  • 2-chloroethyl-dimethylamine 2-chloroethyl-dimethylamine
  • ethylene oxide ethyleneimine
  • dimethyl sulphonate diethyl sulphonate
  • propane sulphone beta-propiolactone
  • diazomethane N-methyl-N-nitrosourethane
  • the progeny, mutant or derivative plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in one or more of the geographical locations hereinbefore described.
  • the present invention also provides reproductive material derived from the plants described herein.
  • reproductive material should be understood as any material from which a plant may be reproduced.
  • "reproductive material” may include seeds, flowers, cuttings, ovaries, ovules, embryo sacs, egg cells, anthers, pollen, regenerable de-differentiated plant tissue such as callus, embryogenic callus or suspension culture, isolated plant embryos and the like.
  • the reproductive material comprises a seed.
  • a plant “seed” should be understood to refer to a mature or immature plant seed.
  • the term “seed” includes, for example, immature seed carried by a maternal plant or seed released from the maternal plant.
  • seed should also be understood to include any seed plant sporophyte between the developmental stages of fertilisation and germination.
  • the term seed refers to a mature plant seed.
  • the seed comprises the seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB
  • the seed comprises the seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41535, or a mutant or derivative thereof.
  • mutants and “derivatives” of the deposited seed.
  • a mutant or derivative of the deposited poppy seed should be understood to encompass, for example, any spontaneous or induced mutant seed, seed from breeding progeny or genetically modified seed, which can produce a poppy plant that retains the ability to produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
  • the present invention also provides straw produced from a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
  • the "straw" of a poppy plant includes fresh or dried tissue of a poppy plant.
  • This tissue may include all or part of the plant, such as root tissue, shoot tissue, floral tissue or a seed capsule.
  • poppy "straw” includes fresh or dried poppy plant tissue which includes a mature seed capsule.
  • the contemplated seed capsule may include seeds, or may be a capsule in which the seeds have been removed.
  • a solvent for example, water or a super critical fluid, such as supercritical CO2
  • a super critical fluid such as supercritical CO2
  • the present invention also provides a poppy straw concentrate produced from a plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
  • poppy straw concentrate should be understood to include any material arising when poppy straw has entered into a process for the concentration of its alkaloids. Not inconsistent with the foregoing definition, "poppy straw concentrates” should also be understood to include any crude or purified extracts of poppy straw in either liquid, solid or powder form which contain one or more phenanthrene alkaloids of an opium poppy.
  • poppy straw concentrates When in liquid form, poppy straw concentrates may be further concentrated from a crude extract. Such concentrates may be either liquid concentrates, wherein a portion of the solvent has been removed, or powder form concentrates which result from removing substantially all of the solvent used for extraction of the poppy straw.
  • a poppy straw concentrate may include all of the alkaloids that may be extracted from a poppy straw, or may include a subset of the extractable alkaloids.
  • a poppy straw concentrate of the present invention at least includes thebaine.
  • the present invention also provides latex derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
  • latex may be obtained by incising an immature seed capsule of the plant, from which latex is exuded.
  • the present invention also provides a stand of stably reproducing poppy plants from which an extractable quantity of thebaine may be produced in the first growing season after germination of the poppy plants, the stand comprising one or more plants according to the first aspect of the invention, or a progeny, mutant or derivative thereof.
  • the present invention also provides a method of producing thebaine, the method comprising growing a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof, such that the plant to produces seed capsules and thebaine in the first growing season after germination; and harvesting thebaine from the poppy plant or a part thereof.
  • the method of the present invention comprises a method for producing thebaine in one or more of the geographical locations hereinbefore described.
  • the present invention provides an isolated cell, tissue or organ derived from the plant of the first aspect of the invention or a progeny plant thereof.
  • the present invention also extends to an in-vitro culture including one or more of the cells described above.
  • Exemplary "in-vitro cultures” contemplated herein include, for example, callus cultures, embryogenic callus cultures, embryo cultures, plantlet cultures and suspension cultures which include one or more of the cells of the invention. Techniques for the establishment and maintenance of plant cell or tissue cultures are well known in the art. In this regard, reference is made to 'Plant Tissue Culture: An Alternative for Production of Useful Metabolites' (FAO Agricultural Services Bulletin No. 108, Food and Agriculture Organization of the United Nations Rome, 1994).
  • a thebaine-producing in-vitro culture of Papaver bracteatum may be established using the method described in US Patent 4,114,314, with the modification that cells derived from the plants of the present invention are used instead of those disclosed in US Patent 4,114,314.
  • the in-vitro cultures of the present invention may be used to produce thebaine.
  • the production of thebaine by the culture may be de novo production, or may be via the conversion of a complex substrate, such as an intermediate in the thebaine biosynthetic pathway, for example, (S)-Reticuline.
  • Figure 1 is a photograph showing the seed capsules of Pc ⁇ aver bracteatum PB-I and Papaver bracteatum PB-2.
  • Papaver bracteatum PB-I which has an indehiscent or closed seed capsule at maturity is shown in the two plants to the right of the photograph, while Papaver bracteatum PB-2, which has a dehiscent or open seed capsule at maturity, is shown in the two plants to the left of the photograph.
  • Papaver bracteatum PB-I Papaver bracteatum PB-2.
  • cultivar PB-I comprises an indehiscent seed capsule
  • cultivar PB-2 comprises a dehiscent seed capsule
  • Plant height at full maturity 1.2 to 1.5 meters
  • Peduncle length 50-80 cm
  • FIG. 1 A photograph showing the differences in the seed capsule between Papaver bracteatum PB-I and Papaver bracteatum PB-2 is shown in Figure 1.
  • Seeds of Papaver bracteatum PB-I and Papaver bracteatum PB-2 were planted in March in Kenya Australia. The plants were allowed to grow and produce seed capsules. Seed capsules were harvested the following February (ie. at the end of the first growing season).
  • the seed capsules were dried to a moisture level of 9 - 16% as determined by a Loss On Drying (LOD) analysis.
  • LOD Loss On Drying
  • Sample of the dried seed capsules from each of the Papaver bracteatum cultivars were finely ground using the laboratory mill. A 3.Og sample was extracted in 10OmL of 10% acetic acid, stirring for 20 minutes. The sample was analysed using gradient elution HPLC using UV detection at 284 nm, referenced to a certified thebaine standard.
  • the assays of first year poppy heads from the two Pa ⁇ aver bracteatum cultivars, PB-I and PB-2 varied from 1.86% to 3.88% anhydrous thebaine by weight of the dried seed capsules.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to poppy cultivars and their use to produce thebaine. In specific forms, the present invention relates to cultivars of Papaver bracteatum that produce thebaine in the first growing season after germination.

Description

CULTIVARS OF THE POPPY PAPAVER BRACTEATUM THAT PRODUCE SEED CAPSULES AND THEBAINE IN THE FIRST GROWING SEASON
PRIORITY CLAIM
The present application claims priority to Australian provisional patent application 2008900325, the contents of which are hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates to poppy cultivars and their use to produce thebaine. In specific forms, the present invention relates to cultivars of Papaver bracteatum that produce thebaine in the first growing season after germination.
BACKGROUND OF THE INVENTION
Opium poppy is commercially cultivated in a number of countries under regulatory control. The latex obtained by the incision of unripe capsules is known as opium and is the source of several pharmacologically important alkaloids. Morphine, codeine, thebaine, narcotine and papaverine are the most important alkaloids produced by the plant, and are exploited by the pharmaceutical industry as analgesics, antitussives and antispasmodics.
On a commercial scale, however, poppy straw and straw concentrate (rather than latex) are the most commonly used raw materials for the production of morphine and other poppy-derived alkaloids. For example, more than 50% of the world's morphine is now manufactured from poppy straw or poppy straw concentrate.
Thebaine is one of the phenanthrene alkaloids contained in opium poppies. Thebaine is dehydromorphine 3,6-dimethyl ether, which has the structure set out below:
Figure imgf000003_0001
The chemical structure of thebaine is superficially similar to both morphine and codeine, but produces stimulatory effects rather than depressant effects. Due to the pharmacological properties of thebaine, it is not generally used therapeutically. However, thebaine may be converted into a variety of pharmaceutical agents including oxycodone, oxymorphone, nalbuphine, naloxone, naltrexone, buprenorphine and etorphine.
Commercially viable cultivars of naturally occurring opium poppy that produce significant quantities of thebaine were unavailable until the development of the 'Norman poppy', a mutant of Pcψaver somniferum (US Patent 6,723,894). This mutant poppy is also an annual, as are other cultivars of Paγaver somniferum.
Prior to the development of this variety, crops of Paγaver somniferum were sprayed with growth regulation chemicals to interrupt alkaloid biosynthetic pathways at an earlier stage, and thus enhance the quantity of thebaine.
Given an increasing world demand for thebaine derived pharmaceuticals, a significantly higher yielding thebaine producing poppy would represent a distinct advantage, particularly if the poppy were also of the perennial type, avoiding the necessity to replant every year, therefore saving farmers the necessity of annual replanting.
Australia produces a significant portion (approximately 30% in 2006) of the world's poppy straw concentrates for morphine production. Furthermore, the Australian State of Tasmania is the world's largest producer of opium alkaloids for the pharmaceutical market. The area sown to poppies in Tasmania was close to 8,000 ha in 2006.
However, a significant problem affecting the cultivation of poppies for thebaine production in at least some poppy growing regions (including Tasmania, Australia) is that high thebaine-yielding varieties, particularly of the species Pcφaver bracteatum, do not produce seed capsules and thebaine in the first growing season after seed germination. Thus, in these regions, commercially viable thebaine poppies cannot be harvested until at least the second growing season after sowing a poppy crop.
Accordingly, there is a need for poppy cultivars that produce extractable quantities of thebaine in the first growing season after germination, particularly cultivars of Pcφaver bracteatum that produce extractable quantities of thebaine in the first growing season after germination in at least temperate poppy-growing regions, such as Tasmania, Australia.
Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.
SUMMARY OF THE INVENTION
The present invention is predicated, in part, on the breeding of poppy cultivars that produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
In some embodiments, the poppy plants of the present invention which produce seed capsules and an extractable quantity of thebaine in the first growing season after germination are of the species Paγaver bracteatum.
In some embodiments, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region. In yet another embodiment, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region in the Southern hemisphere.
In some embodiments, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in Tasmania, Australia.
The present invention also provides reproductive material derived from the plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
In another aspect, the present invention also provides straw produced from a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
In another aspect, the present invention also provides a straw concentrate produced from a plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
In yet another aspect, the present invention also provides latex derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
The present invention also provides a stand of stably reproducing poppy plants from which an extractable quantity of thebaine may be produced in the first growing season after germination of the poppy plants, the stand comprising one or more plants according to the first aspect of the invention, or a progeny, mutant or derivative thereof.
The present invention also extends to a method of producing thebaine, the method comprising growing a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof, such that the plant produces seed capsules and thebaine in the first growing season after germination; and harvesting thebaine from the poppy plant or a part thereof.
In a yet further aspect, the present invention provides an isolated cell derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
The present invention also extends to an in-vitro culture including one or more of the cells described above. Exemplary "in-vitro cultures" contemplated herein include, for example, callus cultures and suspension cultures which include one or more of the cells of the invention. Generally, the in-vitro cultures of the present invention may be used to produce thebaine.
Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.
DESCRIPTION OF EXEMPLARY EMBODIMENTS
It is to be understood that the following description is for the purpose of describing particular embodiments only, and is not intended to be limiting with respect to the above description.
In a first aspect, the present invention provides a poppy plant which produces seed capsules and an extractable quantity of thebaine in the first growing season after germination. As referred to herein, a "poppy plant" should be understood to refer to any thebaine- producing member of the genus Papaver. Exemplary species within the genus Papaver include the Papaver species described in Table 1.
TABLE 1 - Exemplary poppy plants within the genus Papaver
Species Common Name Typical Description
Figure imgf000007_0001
Figure imgf000008_0001
Also, in some embodiments (as described later) the term "poppy" should also be understood to refer to thebaine-producing hybrid plants wherein at least one of the parents is a plant of the genus Paγaver.
In some embodiments, the term "poppy plant" refers to a perennial poppy plant. As referred to herein, a "perennial" poppy plant encompasses poppy plants that produce seed capsules and an extractable quantity of an alkaloid such as thebaine for more than one growing season without the need to replant.
In some embodiments of the invention, the term "poppy plant" refers to a poppy plant of the species Paγaver bracteatum or a hybrid poppy plant wherein at least one of the parents of the hybrid plant is a poppy plant of the species Paγaver bracteatum.
As described below, the term "poppy plant" may also include derivatives and mutants of poppy plants.
In addition, the term poppy plant may refer to a whole poppy plant, but may also refer to a part of a poppy plant, including, for example, reproductive material (such as seeds) derived from a poppy plant; a cell, tissue or organ derived from a poppy plant; and the like.
As set out above, the poppy plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
As referred to herein, the term "thebaine" should be understood as dehydromorphine 3,6-dimethyl ether, which has the structure set out below:
Figure imgf000009_0001
"An extractable quantity of thebaine" should be understood to be any amount of thebaine that may be extracted from the plant, or any part thereof (such as straw or latex).
Methods for the extraction and detection of thebaine are known in the art. For example, thebaine and related alkaloids may be extracted from dried poppy heads and poppy straw using the methods described in French patent 748308, and various modifications thereof. In general, thebaine is extracted from poppy seed capsules using either aqueous acidic extraction conditions or aqueous alkaline extraction conditions to which various water miscible organic solvents have been added.
In some embodiments of the invention "the extractable quantity of thebaine" is a relatively high concentration of thebaine within the plant or a part thereof. In these embodiments, the extractable quantity of thebaine may comprise, for example, anhydrous thebaine comprising at least 1.0% by weight of the seed capsules by weight of a seed capsule of the plant when dried to a moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
In further embodiments, the extractable quantity of anhydrous thebaine may comprise, for example, at least 1.5%, at least 2.0%, at least 2.5%, at least 3.0%, at least 3.5%, at least 3.6%, at least 3.7% or at least 3.8% by weight of the seed capsules by weight of a seed capsule of the plant when dried to a moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
The concentration of thebaine in P. bracteatum seed capsules may by assessed using any suitable method. For example, reference is made to the methods disclosed by Wu and Dobberstein (Journal of Chromatography A 140(1): 65-70, 1977) and Shou et al. (Rapid Communications in Mass Spectrometry 16: 1613-1621, 2002).
Production of seed capsules and an extractable quantity of thebaine "in the first growing season after germination" should be understood as the plants producing seed capsules and an extractable quantity of thebaine within one year of seed germination.
In some embodiments, the plants produce flowers within about 160 days after sowing, and/or are suitable for harvesting and thebaine extraction at about 330 days after sowing.
In some embodiments, the plants of the present invention which produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at a least temperate poppy growing region.
As referred to herein, "a temperate poppy growing region" should be understood as a region in which poppies may be cultivated which is located at a latitude that lies between the tropics and the polar circles. Specifically, the north temperate zone extends from the Tropic of Cancer at about 23.5 degrees north latitude to the Arctic Circle at about 66.5 degrees north latitude. The south temperate zone extends from the Tropic of Capricorn at about 23.5 degrees south latitude to the Antarctic Circle at about 66.5 degrees south Latitude.
In some embodiments, the temperate poppy growing region may include a region where the poppies of the present invention will grow which is at one or more latitudes of about 34°, about 35°, about 36°, about 37°, about 38°, about 39°, about 40°, about 41°, about 42°, about 43°, about 44°, about 45°, about 46°, about 47°, about 48°, about 49°, and/or about 50°.
In some embodiments, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in at least a temperate poppy growing region in the Southern hemisphere. Thus, in some embodiments, the plants of the present invention may produce seed capsules and an extractable quantity of thebaine in the first growing season after germination at one or more latitudes of about 34° S, about 35° S, about 36° S, about 37° S, about 38° S, about 39° S, about 40° S, about 41° S, about 42° S, about 43° S, about 44° S, about 45° S, about 46° S, about 47° S, about 48° S, about 49° S, and/or about 50° S.
Reference herein to a latitude "about" a particular latitude should be understood to encompass latitudes ±0.5° of the defined latitude. In addition, reference to "one or more latitudes" should be understood to encompass discreet ranges of latitudes bounded by any pairs of the specific latitudes mentioned above.
In some embodiments, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination at a latitude of between about 40° S and about 44° S.
In some embodiments, the plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in Tasmania, Australia or a region having substantially equivalent climate.
The average rainfall and temperatures in Tasmania vary considerably across the state. However, in the main poppy growing regions in the north-west and midlands of the state, the typical rainfall is in the range of 600 to 800 mm, and the minimum / maximum temperatures are 2°C and 12°C respectively for July and 12°C and 24°C for January and February. Typically, in Tasmanian poppy growing regions, poppies are planted in March and the dried poppy heads are harvested in the following February.
Reference herein to a "region having substantially equivalent climate" refers to a region having equivalent day length, rainfall and/or seasonal temperature minima and maxima such that conditions under which poppies may be grown are equivalent to those in Tasmania, Australia.
The poppy plants of the present invention may have either a dehiscent (open) seed capsule or an indehiscent (closed) seed capsule at seed maturity.
Wild type P. bracteatum, and most other Papaver species, form pores of dehiscence in the seed capsule at seed maturity, which allows the mature seed in the seed capsule to be released from the seed capsule. However, in some embodiments of the present invention, the poppy cultivar may have seed capsules that have reduced or no pores of dehiscence at the time the seed in the seed capsule has matured. Thus, the trait of an indehiscent or closed seed capsule at maturity leads to the retention of mature seed in the seed capsule in cultivars having the trait.
One significant advantage of the indehiscent or closed seed capsule at maturity trait is that seed is retained on harvesting, and the dispersal of seed is substantially more controlled, minimising excessive plant density with perennial species. Additionally, the seed from cultivars having an indehiscent seed capsule can be readily collected from the seed capsule and further utilised. Two exemplary poppy cultivars of the present invention have been deposited in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
Seed from the first exemplary cultivar, referred to herein as PB-I, having an indehiscent or closed seed capsule at maturity, has been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41534.
Accordingly, in one specific embodiment, the plant of the first aspect of the invention is produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41534; or a progeny, mutant or derivative of said plant that retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
Seed from the second exemplary cultivar, referred to herein as PB-2, having a dehiscent or open seed capsule at maturity, has been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41535.
Accordingly, in another specific embodiment, the plant of the first aspect of the invention is produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB; or a progeny, mutant or derivative of said plant that retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
The present invention also provides a progeny plant, wherein the progeny plant has a plant of the first aspect of the invention as a parent, and wherein said progeny plant produces an extractable quantity of thebaine in the first growing season after germination. As referred to herein, a "progeny" plant may be any plant for which a plant of the first aspect of the invention is at least one of the parents. Thus, the progeny plant may be a plant resulting from self-fertilisation of a plant of the first aspect of the invention; a plant resulting from a non-self fertilisation wherein a plant of the first aspect of the invention is the male or female parent; an intrageneric hybrid plant wherein one of the parents is a plant of the first aspect of the invention and the other parent is a plant within the genus Papaver; an intergeneric hybrid plant wherein one of the parents is a plant of the first aspect of the invention and the other parent is a plant of a genus other than Papaver, an asexually produced progeny of a plant of the first aspect of the invention, such as vegetatively reproduced progeny or progeny produced by apomixis.
The present invention also provides a mutant or derivative of the poppy plant of the first aspect of the invention wherein the mutant or derivative produces seed capsules an extractable quantity of thebaine in the first growing season after germination.
A "mutant or derivative" of the subject poppy plants should be understood to encompass, for example, any spontaneous or induced mutant, breeding progeny or genetically modified form of the deposited strains which retains the ability to produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
Mutagenisation techniques that may be used to generate derivatives or mutants of the deposited poppy cultivars include, for example, chemical mutagenesis (eg. EMS mutagenesis), ionising radiation-induced mutagenesis (eg. X-ray mutagenesis, γ-ray mutagenesis and UV mutagenesis), genetic insertion mutagenesis methods (eg. transposon mutagenesis or T-DNA mutagenesis) and the like. Techniques for the production of mutagenized seed are well known in the art. For example, methods of seed mutagenesis as well as chemical mutagens suitable for use in these methods are described in, for example, The Manual on Mutation Breeding, 2nd ed. (I.A.E.A., Vienna, 1977) or in Plant Breeding, Principles and Prospects (Chapman and Hall, London, 1993). Example mutagens include ethyl methanesulfonate (EMS), diepoxybutane (DEB) ethyl- 2-chloroethyl sulphide, 2-chloroethyl-dimethylamine, ethylene oxide, ethyleneimine, dimethyl sulphonate, diethyl sulphonate, propane sulphone, beta-propiolactone, diazomethane, N-methyl-N-nitrosourethane, acridine orange and sodium azide. An example of ionising radiation induced mutagenesis, specifically X-ray mutagenesis is described and compared to EMS mutagenesis by Filippetti et al. (Euphytica 35: 49-59, 1986).
In some embodiments, the progeny, mutant or derivative plants of the present invention produce seed capsules and an extractable quantity of thebaine in the first growing season after germination in one or more of the geographical locations hereinbefore described.
The present invention also provides reproductive material derived from the plants described herein. The term "reproductive material" should be understood as any material from which a plant may be reproduced. For example, "reproductive material" may include seeds, flowers, cuttings, ovaries, ovules, embryo sacs, egg cells, anthers, pollen, regenerable de-differentiated plant tissue such as callus, embryogenic callus or suspension culture, isolated plant embryos and the like.
In some embodiments, the reproductive material comprises a seed. As referred to herein, a plant "seed" should be understood to refer to a mature or immature plant seed. As such, the term "seed" includes, for example, immature seed carried by a maternal plant or seed released from the maternal plant. The term "seed" should also be understood to include any seed plant sporophyte between the developmental stages of fertilisation and germination. However, in some embodiments, the term seed refers to a mature plant seed.
In one specific embodiment, the seed comprises the seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB
41534, or a mutant or derivative thereof. In another specific embodiment, the seed comprises the seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41535, or a mutant or derivative thereof.
The above embodiments of the invention refer to "mutants" and "derivatives" of the deposited seed. A mutant or derivative of the deposited poppy seed should be understood to encompass, for example, any spontaneous or induced mutant seed, seed from breeding progeny or genetically modified seed, which can produce a poppy plant that retains the ability to produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
In another aspect, the present invention also provides straw produced from a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof.
As defined herein the "straw" of a poppy plant includes fresh or dried tissue of a poppy plant. This tissue may include all or part of the plant, such as root tissue, shoot tissue, floral tissue or a seed capsule. In some embodiments, poppy "straw" includes fresh or dried poppy plant tissue which includes a mature seed capsule. The contemplated seed capsule may include seeds, or may be a capsule in which the seeds have been removed.
Methods for poppy straw processing to obtain alkaloids are well known in the art. However, by way of example, reference is made to French patent 748308 which discloses one example of a method for alkaloid extraction from poppy straw.
A solvent (for example, water or a super critical fluid, such as supercritical CO2) may also be used to extract alkaloids from straw. Extracts produced according to such methods include "straw concentrates".
Thus, in another aspect, the present invention also provides a poppy straw concentrate produced from a plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
The term "poppy straw concentrate" should be understood to include any material arising when poppy straw has entered into a process for the concentration of its alkaloids. Not inconsistent with the foregoing definition, "poppy straw concentrates" should also be understood to include any crude or purified extracts of poppy straw in either liquid, solid or powder form which contain one or more phenanthrene alkaloids of an opium poppy.
When in liquid form, poppy straw concentrates may be further concentrated from a crude extract. Such concentrates may be either liquid concentrates, wherein a portion of the solvent has been removed, or powder form concentrates which result from removing substantially all of the solvent used for extraction of the poppy straw.
A poppy straw concentrate, as defined herein, may include all of the alkaloids that may be extracted from a poppy straw, or may include a subset of the extractable alkaloids. Generally, a poppy straw concentrate of the present invention at least includes thebaine.
In another aspect, the present invention also provides latex derived from the plant of the first aspect of the invention or a progeny, mutant or derivative thereof.
Methods for obtaining latex from a poppy plant, including Paγaver bracteatum, are well known in the art. Generally, latex may be obtained by incising an immature seed capsule of the plant, from which latex is exuded.
In another aspect, the present invention also provides a stand of stably reproducing poppy plants from which an extractable quantity of thebaine may be produced in the first growing season after germination of the poppy plants, the stand comprising one or more plants according to the first aspect of the invention, or a progeny, mutant or derivative thereof. In yet another aspect, the present invention also provides a method of producing thebaine, the method comprising growing a plant of the first aspect of the invention, or a progeny, mutant or derivative thereof, such that the plant to produces seed capsules and thebaine in the first growing season after germination; and harvesting thebaine from the poppy plant or a part thereof.
In various embodiments, the method of the present invention comprises a method for producing thebaine in one or more of the geographical locations hereinbefore described.
In a yet further aspect, the present invention provides an isolated cell, tissue or organ derived from the plant of the first aspect of the invention or a progeny plant thereof.
The present invention also extends to an in-vitro culture including one or more of the cells described above. Exemplary "in-vitro cultures" contemplated herein include, for example, callus cultures, embryogenic callus cultures, embryo cultures, plantlet cultures and suspension cultures which include one or more of the cells of the invention. Techniques for the establishment and maintenance of plant cell or tissue cultures are well known in the art. In this regard, reference is made to 'Plant Tissue Culture: An Alternative for Production of Useful Metabolites' (FAO Agricultural Services Bulletin No. 108, Food and Agriculture Organization of the United Nations Rome, 1994).
In some embodiments, a thebaine-producing in-vitro culture of Papaver bracteatum may be established using the method described in US Patent 4,114,314, with the modification that cells derived from the plants of the present invention are used instead of those disclosed in US Patent 4,114,314.
Generally, the in-vitro cultures of the present invention may be used to produce thebaine. The production of thebaine by the culture may be de novo production, or may be via the conversion of a complex substrate, such as an intermediate in the thebaine biosynthetic pathway, for example, (S)-Reticuline.
The present invention is further described by the following non-limiting examples:
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a photograph showing the seed capsules of Pcφaver bracteatum PB-I and Papaver bracteatum PB-2. Papaver bracteatum PB-I, which has an indehiscent or closed seed capsule at maturity is shown in the two plants to the right of the photograph, while Papaver bracteatum PB-2, which has a dehiscent or open seed capsule at maturity, is shown in the two plants to the left of the photograph.
EXAMPLE 1 Morphological description of Papaver bracteatum PB-I and Papaver bracteatum PB-2
Presented below are selected morphological characteristics of two bred poppy cultivars, Papaver bracteatum PB-I and Papaver bracteatum PB-2.
Each of the cultivars has substantially identical morphological characteristics other than that cultivar PB-I comprises an indehiscent seed capsule, while cultivar PB-2 comprises a dehiscent seed capsule. A summary of the morphological characteristics of the cultivars is shown below:
Plant height at full maturity: 1.2 to 1.5 meters
Peduncle length: 50-80 cm,
Peduncle colour green, light brown later prior to harvest.
Number of capsules: 1 - 17 capsules per plant.
Capsule dehiscence at maturity: PB-I - indehiscent PB-2 - dehiscent
Capsule size: 1.4 - 4.7g % total weight seed: 39 - 54%
LOD: 9 - 12%
Anhydrous Assay: 2 - 5%
Mass of one seed: 0.00023g Seeds per capsule: 9,000 - 12,000
Days to flowering: approx 160 days.
Days to harvest: approx 330 days.
A photograph showing the differences in the seed capsule between Papaver bracteatum PB-I and Papaver bracteatum PB-2 is shown in Figure 1.
Seeds of Papaver bracteatum PB-I have been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41534.
Seeds of Papaver bracteatum PB-2 have been deposited at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on 3 January 2008 under accession number NCIMB 41535.
EXAMPLE 2
Thebaine production in Papaver bracteatum PB-I and Papaver bracteatum PB-2
Seeds of Papaver bracteatum PB-I and Papaver bracteatum PB-2 were planted in March in Tasmania Australia. The plants were allowed to grow and produce seed capsules. Seed capsules were harvested the following February (ie. at the end of the first growing season).
The seed capsules were dried to a moisture level of 9 - 16% as determined by a Loss On Drying (LOD) analysis.
Sample of the dried seed capsules from each of the Papaver bracteatum cultivars were finely ground using the laboratory mill. A 3.Og sample was extracted in 10OmL of 10% acetic acid, stirring for 20 minutes. The sample was analysed using gradient elution HPLC using UV detection at 284 nm, referenced to a certified thebaine standard.
The assays of first year poppy heads from the two Paγaver bracteatum cultivars, PB-I and PB-2 varied from 1.86% to 3.88% anhydrous thebaine by weight of the dried seed capsules.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to, or indicated in this specification, individually or collectively, and any and all combinations of any two or more of the steps or features.

Claims

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. A poppy plant that produces seed capsules and an extractable quantity of thebaine in the first growing season after germination.
2. The plant of claim 1 wherein the poppy plant is a perennial poppy plant.
3. The plant of claim 1 or 2 wherein the poppy plant is of the species Pcφaver bracteatum.
4. The plant of any one of claims 1 to 3 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination in a temperate poppy growing region.
5. The plant of any one of claims 1 to 4 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination at a latitude of between 40° and 44°.
6. The plant of any one of claims 1 to 5 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination in
Tasmania, Australia.
7. The plant of any one of claims 1 to 6 wherein the extractable quantity of thebaine is anhydrous thebaine comprising at least 1.0% by weight of a seed capsule of the plant when dried to moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
8. A poppy plant produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41534; or a progeny, mutant or derivative of said plant that retains the ability to produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
9. A poppy plant produced from seed deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41535; or a progeny, mutant or derivative of said plant that retains the ability to produce seed capsules and an extractable quantity of thebaine in the first growing season after germination.
10. The plant of claim any one of claims 1 to 8 wherein the plant comprises an indehiscent seed capsule.
11. The plant of claim any one of claims 1 to 7 or 9 wherein the plant comprises a dehiscent seed capsule.
12. A progeny plant, having the plant of any one of claims 1 to 11 as a parent, wherein said progeny plant produces seed capsules an extractable quantity of thebaine in the first growing season after germination.
13. The plant of claim 11 wherein the plant is of the species Papaver bracteatum.
14. A mutant or derivative plant of the plant of any one of claims 1 to 13 wherein the mutant or derivative produces seed capsules an extractable quantity of thebaine in the first growing season after germination.
15. The progeny, mutant or derivative plant of any one of claims 12 to 14 wherein the progeny, mutant or derivative plant is a perennial poppy plant.
16. The progeny, mutant or derivative plant of any one of claims 12 to 15 wherein the plant is of the species Papaver bracteatum.
17. The progeny, mutant or derivative plant of any one of claims 12 to 16 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination in a temperate poppy growing region.
18. The progeny, mutant or derivative plant of any one of claims 12 to 17 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination at a latitude of between 40° and 44°.
19. The progeny, mutant or derivative plant of any one of claims 12 to 18 wherein the plant produces seed capsules and an extractable quantity of thebaine in the first growing season after germination in Tasmania, Australia.
20. The progeny, mutant or derivative plant of any one of claims 12 to 19 wherein the extractable quantity of thebaine is anhydrous thebaine comprising at least 1.0% by weight of a seed capsule of the plant when dried to a moisture level of 9-16% as determined by a Loss On Drying (LOD) analysis.
21. Reproductive material derived from the plant of any one of claims 1 to 20.
22. The reproductive material of claim 21 wherein the reproductive material comprises a seed.
23. A seed as deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41534, or a mutant or derivative thereof.
24. A seed as deposited with the National Collections of Industrial and Marine Bacteria Limited under accession number NCIMB 41535 or a mutant or derivative thereof.
25. Straw produced from the plant of any one of claims 1 to 20.
26. A straw concentrate produced from the plant of any one of claims 1 to 20 or the straw of claim 25.
27. Latex derived from the plant of any one of claims 1 to 20.
28. A method of producing thebaine, the method comprising growing a poppy plant according to any one of claims 1 to 20 such that the plant produces seed capsules and thebaine in the first growing season after germination; and harvesting thebaine from the poppy plant or a part thereof.
29. Thebaine produced according to the method of claim 28.
30. A stand of stably reproducing poppy plants from which an extractable quantity of thebaine may be produced in the first growing season after germination of the poppy plants, the stand comprising one or more plants according to any one of claims 1 to 20.
31. An isolated cell derived from the plant of any one of claims 1 to 20.
32. An in-vitro culture comprising one or more of the cells of claim 31.
33. The in-vitro culture of claim 32 wherein said culture produces thebaine.
PCT/AU2009/000065 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season WO2009092134A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2009801090411A CN101969760A (en) 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season
US12/735,548 US20110047653A1 (en) 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season
AU2009208009A AU2009208009B2 (en) 2008-01-24 2009-01-22 Cultivars of the poppy Papaver bracteatum that produce seed capsules and thebaine in the first growing season
EP20090703922 EP2234473A4 (en) 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season
NZ586953A NZ586953A (en) 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season
ZA2010/05619A ZA201005619B (en) 2008-01-24 2010-08-05 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008900325 2008-01-24
AU2008900325A AU2008900325A0 (en) 2008-01-24 Poppy

Publications (1)

Publication Number Publication Date
WO2009092134A1 true WO2009092134A1 (en) 2009-07-30

Family

ID=40900731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/000065 WO2009092134A1 (en) 2008-01-24 2009-01-22 Cultivars of the poppy papaver bracteatum that produce seed capsules and thebaine in the first growing season

Country Status (7)

Country Link
US (1) US20110047653A1 (en)
EP (1) EP2234473A4 (en)
CN (1) CN101969760A (en)
AU (1) AU2009208009B2 (en)
NZ (1) NZ586953A (en)
WO (1) WO2009092134A1 (en)
ZA (1) ZA201005619B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635107A1 (en) * 2010-11-01 2013-09-11 TPI Enterprises Ltd. Papaver bracteatum with modified alkaloid content
US10760090B2 (en) 2008-03-07 2020-09-01 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine
US10791691B2 (en) 2008-05-29 2020-10-06 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum with high concentration of codeine
AU2018203033B2 (en) * 2017-05-02 2021-07-01 Sun Pharmaceutical Industries Australia Pty Limited Modified plant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144314A (en) * 1976-10-01 1979-03-13 Metallgesellschaft Aktiengesellschaft Process for regenerating water-containing methanol
US20040221506A1 (en) * 2003-05-06 2004-11-11 Tisserat Brent H. Tissue culture of plant material enriched in a secondary metabolites

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD112648A1 (en) * 1972-10-13 1975-04-20
US4114314A (en) * 1977-02-22 1978-09-19 The Ministry Of Science & Higher Education Process for the production of thebaine
US6067749A (en) * 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144314A (en) * 1976-10-01 1979-03-13 Metallgesellschaft Aktiengesellschaft Process for regenerating water-containing methanol
US20040221506A1 (en) * 2003-05-06 2004-11-11 Tisserat Brent H. Tissue culture of plant material enriched in a secondary metabolites

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Acta Hortic. Third International Symposium on Spice and Medicinal Plants, April 1983", vol. 132, article PALEVITCH, D. ET AL.: "Cultural and Genetic Factors Affecting Thebaine yield in Papaver Bracteatum Lindl..", pages: 189 - 195 *
BARE, C.E. ET AL.: "Growth, Development and Thebaine Content of Papaver bracteatum Lindl. In Relation to Spacing.", AGRON. J., vol. 79, no. ISS. 5, September 1987 (1987-09-01), pages 935 - 937 *
See also references of EP2234473A4 *
WOLD, J.K. ET AL.: "Increase in Thebaine Content ofPapaver bracteatum, Lindl. After Colchicine Treatment of Seeds.", ACTA PHARMA. NORD., vol. 4, no. 1, 1992, pages 31 - 34 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760090B2 (en) 2008-03-07 2020-09-01 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine
US10791691B2 (en) 2008-05-29 2020-10-06 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum with high concentration of codeine
EP2635107A1 (en) * 2010-11-01 2013-09-11 TPI Enterprises Ltd. Papaver bracteatum with modified alkaloid content
EP2635107A4 (en) * 2010-11-01 2014-04-23 Tpi Entpr Ltd Papaver bracteatum with modified alkaloid content
AU2018203033B2 (en) * 2017-05-02 2021-07-01 Sun Pharmaceutical Industries Australia Pty Limited Modified plant

Also Published As

Publication number Publication date
NZ586953A (en) 2012-07-27
EP2234473A1 (en) 2010-10-06
US20110047653A1 (en) 2011-02-24
EP2234473A4 (en) 2011-01-12
AU2009208009A1 (en) 2009-07-30
AU2009208009B2 (en) 2014-08-07
ZA201005619B (en) 2011-04-28
CN101969760A (en) 2011-02-09

Similar Documents

Publication Publication Date Title
AU2017100067A4 (en) Papaver somniferum with high concentration of codeine
AU2017322099B2 (en) P. somniferum plants for the production of codeine
Fatokun et al. Interspecific hybridization between Vigna pubescens and V. unquiculata (L.) Walp through embryo rescue
AU2009208009B2 (en) Cultivars of the poppy Papaver bracteatum that produce seed capsules and thebaine in the first growing season
US20050257295A1 (en) Production of reticuline
M’Ribu et al. Fertility of doubled monoploids of Solanum phureja
GB2142535A (en) Preparation of a pharmaceutical camomile product
AU2020277294B2 (en) A Plant
KR20180133732A (en) New Aralia elata variety
AU2018100457A4 (en) P. somniferum Plants for the Production of Codeine
US8680369B2 (en) Sunn hemp cultivars capable of producing seed within the continental united states
ES2964577T3 (en) Papaver somniferum with high concentration of codeine
Hiraoka et al. Micropropagation of Corydalis ambigua through embryogenesis of tuber sections and chemical evaluation of the ramets
FI81007C (en) Procedure for Obtaining a Substance with Anti-Inflammatory Effect in Matricaria chamomilla
Mevenkamp et al. Baptisia tinctoria (L.) R. Brown: Micropropagation, In Vitro Culture and Production in Direction of Pharmaceutically Used Root Biomass

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980109041.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09703922

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 586953

Country of ref document: NZ

Ref document number: 2009703922

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009208009

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4827/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009208009

Country of ref document: AU

Date of ref document: 20090122

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12735548

Country of ref document: US